Order Article Reprints

Sailer N, Fetzer I, Salvermoser M, Braun M, Brechtefeld D, Krendl C, Geiger C, Mutze K, Noessner E, Schendel DJ, et al. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers. 2022; 14(8):1998. https://doi.org/10.3390/cancers14081998

Sailer, Nadja, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, and et al. 2022. "T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity" Cancers 14, no. 8: 1998. https://doi.org/10.3390/cancers14081998

Sailer, N., Fetzer, I., Salvermoser, M., Braun, M., Brechtefeld, D., Krendl, C., Geiger, C., Mutze, K., Noessner, E., Schendel, D. J., Bürdek, M., Wilde, S., & Sommermeyer, D. (2022). T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers, 14(8), 1998. https://doi.org/10.3390/cancers14081998